SkinBioTherapeutics PLC - Newcastle-based life science company focused on skin health - Extends its collaboration contract with Sederma SAS, the cosmetics arm of Croda International PLC, for another 12 months. Says the extension is so Sederma can complete and assess further studies on SkinBiotix technology to look at ‘previously unseen beneficial properties’, which could ‘significantly enhance commercial opportunities’. Sederma will cover any costs of SkinBioTherapeutics concerning the supply of SkinBiotix for the studies.‘We are confident that this can lead to a wider commercialisation of our SkinbiotixTM technology into new products, which can make a great difference to consumers with a wide array of skincare needs,’ says CEO Stuart Ashman.

Current stock price: 20.91 pence, down 2.7%

12-month change: up 13%

Copyright 2023 Alliance News Ltd. All Rights Reserved.